Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
41 hedge funds and large institutions have $38.8M invested in Lumos Pharma, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 11 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
13% less funds holding
Funds holding: 47 → 41 (-6)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
71% less capital invested
Capital invested by funds: $135M → $38.8M (-$95.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.61M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$814K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$588K |
| 4 |
Renaissance Technologies
New York
|
+$397K |
| 5 |
IFG
Investors Financial Group
Plymouth,
Minnesota
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$9.47M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.33M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$588K |
| 4 |
TYCC
Texas Yale Capital Corp
St. Petersburg,
Florida
|
-$571K |
| 5 |
6CM
683 Capital Management
New York
|
-$375K |
LUMO Hedge Fund Activity: Q1 2021 in Review
41 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2021, worth a combined $38.8M — down 71% from $135M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LUMO and 6 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 12 added.
The largest buyer was Opaleye Management, adding an estimated $1.61M. The largest seller was Deerfield Management, cutting an estimated $9.47M.
- 41 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2021, down from 47 in Q4 2020.
- Funds reported $38.8M of Lumos Pharma, Inc. Common Stock stock for Q1 2021, down 71% quarter-over-quarter.
- 6 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2021 and 11 closed out, a net change of -5 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2021 was Opaleye Management, an estimated $1.61M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2021 was Deerfield Management, an estimated $9.47M sold.
Based on aggregated 13F filings for Q1 2021.